首页 | 本学科首页   官方微博 | 高级检索  
     


Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
Authors:P D Kroboth   R B Smith   M R Silver   R Rault   M I Sorkin   J B Puschett     R P Juhl
Abstract:Triazolam 0.5 mg was administered to 11 dialysis patients and 11 age, weight and sex matched controls. Peak plasma concentrations (Cmax) were higher in control subjects, but there were no other differences between the groups. When dialysis patients took triazolam with 3600 mg aluminum hydroxide suspension, Cmax and AUC were increased into the range observed in control subjects. It appears that triazolam can be used at normal doses in patients with renal dysfunction, without regard to interaction with aluminum hydroxide gel, or to alterations in elimination.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号